<DOC>
	<DOCNO>NCT00050167</DOCNO>
	<brief_summary>Primary Objectives : - Determine impact regimen disease free overall survival patient operable breast cancer . - Determine ability docetaxel/capecitabine downstage primary breast cancer administer neoadjuvant setting compare weekly paclitaxel . - Determine ability regimen enhance breast conservation therapy administer neoadjuvant setting . ( See protocol text additional objective detail ) .</brief_summary>
	<brief_title>Evaluation Differing Taxanes/Taxane Combinations Outcome Patients With Operable Breast Cancer</brief_title>
	<detailed_description>Before study , participant complete physical exam , include blood test chest x-ray . A mammogram sonogram breast armpit do record tumor size ( patient surgery ) . Sonography liver CT scan abdomen also do . In patient surgery , 3-4 sample breast tumor take help confirm diagnosis breast cancer . A biopsy needle use collect sample . During study , participant blood test do dose chemotherapy . For participant surgery , mammogram sonogram do breast armpit completion paclitaxel docetaxel/capecitabine completion fluorouracil , cyclophosphamide , epirubicin ( FEC ) . These study help doctor keep track tumor size help final decision whether remove part breast nearby lymph node completion chemotherapy . Participants study randomly assign ( toss coin ) one two treatment group . There equal chance either group . Participants Group I receive paclitaxel week . The drug give plastic tube vein 1 hour total 12 treatment . Before treatment , patient receive drug Decadron ( dexamethasone ) vein may receive Zofran ( ondansetron ) , Benadryl ( diphenhydramine hydrochloride ) and/or cimetidine help decrease risk side effect paclitaxel . Participants Group II receive docetaxel capecitabine . Docetaxel give every 3 week . Docetaxel give plastic tube vein 1 hour . Capecitabine start day docetaxel give . This medicine give pill form . The doctor prescribe dose pill base upon body weight height . Participants take several pill two time day 14 day . Participants take capecitabine pill one week , next dose docetaxel give . This combination docetaxel capecitabine give four time ( period 12 week ) . Before treatment , patient receive drug Decadron ( dexamethasone ) mouth . After treatment either paclitaxel docetaxel/capecitabine , participant receive drug FEC plastic tube vein . All drug give every three week total 4 treatment ( 12 week total ) . Decadron ( dexamethasone ) , Zofran ( ondansetron ) Benadryl ( diphenhydramine hydrochloride ) give chemotherapy help decrease risk side effect . Participants Her-2/neu positive cancer potentially eligible receive trastuzumab therapy 1 year . This medicine give vein either week ( 30 minute ) every 3 week ( 30 minute ) . Your doctor discus whether medicine appropriate . After treatment do , participant whose tumor sensitive hormone ( estrogen ) take pill help decrease amount hormone ( estrogen ) reach tumor cell . This pill take day 5 year . Participants complete surgery cancer receive chemotherapy describe surgery remove part breast cancer . If sign lymph node armpit ( axilla ) contain cancer , lymph node also remove . After chemotherapy surgery , completion chemotherapy ( patient surgery do first ) , participant may receive radiation treatment breast area armpit day ( Monday Friday ) 5-6 week . After study , participant return checkup every 3-4 month Years 1 2 , every 6 month year 3 4 yearly . During check-ups participant talk examine physician . Once year , patient yearly mammogram ( need ) , chest-x ray , blood test . This investigational study . All drug study approve FDA treatment breast cancer . A total 930 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Patients histologic confirmation invasive , noninflammatory carcinoma breast . 2 . Stage I ( T1N0 ) eligible neoadjuvant portion protocol . 3 . Highrisk patient ( patient follow : high proliferation rate Ki67 &gt; 35 % poorly differentiate tumor ( black 's modify grade 3 ) ; ER/PR negative ; lymphovascular invasion ) stage I disease eligible adjuvant therapy . 4 . Patients pure mucinous carcinoma , tubular carcinoma pure medullary carcinoma eligible patient 's tumor large 3 cm size patient tumor involvement lymph node ( &gt; 2mm ) . 5 . Patients bilateral breast cancer eligible . 6 . Patients pN2a ( metastasis four nine axillary lymph node ) eligible patient pN3a ( ten axillary lymph node ) . Patients infraclavicular lymph node involvement NOT eligible . 7 . Patients must clinically measurable disease treat neoadjuvant setting . This include patient nonpalpable primary histologically proven lymph node ( LN ) involvement clinically palpable measurable ultrasound 8 . Histologic confirmation invasive tumor do core needle biopsy patient intact primary tumor . If patient undergone adequate core biopsy prior evaluation MDACC , repeat core biopsy optional . 9 . Patients must sign informed consent indicate aware investigational nature study , keep institutional policy . 10 . Patients prior history breast cancer eligible current primary breast cancer high stage original breast cancer patient receive current study medication include past doxorubicin . 11 . Patients adequate bone marrow function , define peripheral granulocyte count &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 . Patients must adequate liver function bilirubin within normal laboratory value . Transaminases ( SGPT ) may 2.5x upper limit normal ( ULN ) alkaline phosphatase &lt; ULN alkaline phosphatase may 4 x ULN transaminases &lt; ULN . 12 . In addition , patient adequate renal function , define serum creatinine &lt; 2.5 mg % and/or creatinine clearance great 51 ml/min calculate Cockcroft Gault Equation : Cockcroft Gault Equation : Creatinine clearance male = { ( 140 age [ yr ] ) ( body weight [ kg ] ) } / { ( 72 ) ( serum creatinine [ mg/dL ] ) } . Creatinine clearance female = 0.85 x male value 13 . Patients surgical therapy prior referral eligible randomization systemic chemotherapy administer adjuvant setting . 14 . Patients overexpression her2/neu oncogene eligible study . 1 . Patients N2 ( clinical staging ) N3 ( clinical staging ) nodal disease , inflammatory breast cancer , metastatic disease eligible . This include patient infraclavicular and/or supraclavicular lymph node involvement . Patients pN2a ( metastasis four nine axillary lymph node ) eligible . 2 . Patients pN2b ( metastasis clinically apparent internal mammary lymph node absence axillary lymph node metastasis ) eligible . Patients T4 lesion neoadjuvant set eligible . Patients limited T4 lesion adjuvant set ( example , focal extension skin negative margin ) eligible . 3 . Severe hypersensitivity reaction agent formulate either cremophor polysorbate 80 must exclude . Patients hypersensitivity reaction study medication must exclude . 4 . Those patient history malignancy exclude , except nonmelanoma skin cancer noninvasive cervical cancer . 5 . Patients uncompensated congestive heart failure eligible . Patients myocardial infarction within past 12 month ineligible . 6 . Patients pregnant lactate eligible . Women childbearing potential must negative pregnancy test prior initiation chemotherapy . Women childbearing potential use reliable appropriate contraceptive method study eligible . 7 . Patients organ allograft ineligible . 8 . Patients serious concurrent infection ineligible . 9 . Sexually active male patient unwilling practice contraception study ineligible . 10 . Patients preexist peripheral neuropathy &gt; grade 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Taxol</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Taxanes</keyword>
	<keyword>Operable Breast Cancer</keyword>
</DOC>